Recursion Announces
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
September 05, 2023 07:59 ET | Recursion Pharmaceuticals
SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has...
IMC Logo.jpg
Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease
January 17, 2023 07:10 ET | Immuron Limited
MELBOURNE, Australia, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...
Finch_Short_Logo_L.png
Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results
November 10, 2022 07:00 ET | Finch Therapeutics Group, Inc.
Patient dosing underway in PRISM4 Phase 3 trial of CP101 in recurrent CDITopline PRISM4 data anticipated in H1 2024 Anticipated cash runway into Q2 2024 SOMERVILLE, Mass., Nov. 10, 2022 (GLOBE...
Finch_Short_Logo_L.png
Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference
November 09, 2022 08:00 ET | Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch_Short_Logo_L.png
Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection
October 24, 2022 08:00 ET | Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
IMC Logo.jpg
Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease
July 07, 2022 06:00 ET | Immuron Limited
MELBOURNE, Australia, July 07, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
AP Party logo with leaf-black.jpg
Animal Agriculture a Ticking Time-Bomb for Zoonotic Disease Transmission warns Animal Protection Party of Canada
April 28, 2022 13:49 ET | Animal Protection Party of Canada
TORONTO, April 28, 2022 (GLOBE NEWSWIRE) -- The potential for another major animal to human zoonotic disease outbreak is very real according to the findings of a recent study, warns the Animal...
Summit Master_rgb_png.png
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2020
March 17, 2021 07:00 ET | Summit Therapeutics plc
Summit Therapeutics Inc.(‘Summit’ or the ‘Company’) Cambridge, MA, March 17, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on...
Summit Master_rgb_png.png
Summit Announces a Proposed Subscription and Placing to Raise approximately $50.0 Million and Notice of General Meeting
December 06, 2019 07:00 ET | Summit Therapeutics plc
THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, OR...
Summit Master_rgb_png.png
Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection
February 13, 2019 07:00 ET | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection Trials Aim to Show...